Growth Hormone Peptides and TRH Affect Leptin and Metabolism in Critically Ill Patients
In critically ill patients wasting muscle while gaining fat, GHRP-2 combined with TRH reduced leptin levels and improved the hormonal profile associated with the catabolic state.
Quick Facts
What This Study Found
GHRP-2 combined with TRH infusion reduced elevated leptin levels and reactivated suppressed GH and thyroid axes in prolonged critically ill patients, addressing the paradoxical fat-gain/muscle-wasting metabolic state.
Key Numbers
How They Did This
Randomized controlled trial in prolonged critically ill ICU patients. Continuous IV infusions of GHRP-2, TRH, and their combination were tested. Leptin, GH, IGF-1, thyroid hormones, and metabolic markers measured.
Why This Research Matters
Muscle wasting in ICU patients dramatically increases mortality and recovery time. Correcting the underlying hormonal dysfunction with peptide therapy could preserve muscle and improve survival in this vulnerable population.
The Bigger Picture
Critical illness creates complex metabolic disruption that resists conventional nutrition support. Targeting the hormonal causes of ICU wasting with specific peptides represents a fundamentally different approach to this major clinical problem.
What This Study Doesn't Tell Us
ICU patient population is heterogeneous. Short-term hormonal changes may not translate to improved clinical outcomes. Small study with inherent challenges of critical care research.
Questions This Raises
- ?Does correcting leptin and GH levels actually prevent muscle wasting in ICU patients?
- ?What is the optimal duration of peptide therapy in critical illness?
- ?Could early peptide intervention prevent the catabolic state from developing?
Trust & Context
- Key Stat:
- Leptin reduced Combined GHRP-2 and TRH lowered pathologically elevated leptin while reactivating the suppressed growth and thyroid hormone axes in ICU patients
- Evidence Grade:
- Moderate evidence from a randomized trial in a challenging ICU population, with clear hormonal endpoints but limited clinical outcome data.
- Study Age:
- Published in 1998. Research on GH secretagogues in critical illness has continued, with larger trials examining clinical outcomes.
- Original Title:
- Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
- Published In:
- The Journal of clinical endocrinology and metabolism, 83(9), 3062-70 (1998)
- Authors:
- Van den Berghe, G(10), Wouters, P(7), Carlsson, L, Baxter, R C, Bouillon, R, Bowers, C Y
- Database ID:
- RPEP-00500
Evidence Hierarchy
Frequently Asked Questions
Why do ICU patients lose muscle while gaining fat?
Critical illness suppresses growth hormone and thyroid hormones while raising cortisol and leptin. This creates a metabolic state where the body breaks down muscle for energy while storing fat, even with adequate nutrition.
Could peptide therapy save lives in the ICU?
By correcting the hormonal dysfunction that drives muscle wasting, peptide therapy could help ICU patients maintain strength for recovery. Muscle loss is a major contributor to prolonged ICU stays and death, so addressing it has significant survival implications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00500APA
Van den Berghe, G; Wouters, P; Carlsson, L; Baxter, R C; Bouillon, R; Bowers, C Y. (1998). Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.. The Journal of clinical endocrinology and metabolism, 83(9), 3062-70.
MLA
Van den Berghe, G, et al. "Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.." The Journal of clinical endocrinology and metabolism, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Leptin levels in protracted critical illness: effects of gro..." RPEP-00500. Retrieved from https://rethinkpeptides.com/research/van-1998-leptin-levels-in-protracted
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.